山東新華製藥股份(00719.HK)建議採納股票期權計劃
格隆匯10月28日丨山東新華製藥股份(00719.HK)公吿,公司謹此公佈,董事會已通過建議的股票期權計劃及其建議的授予。股票期權計劃須經國資委備案及將由股東於臨時股東大會以及類別股東大會批准(包括華魯控股批准)後生效。股票期權計劃可能根據國資委的要求進行修改。
股票期權計劃目的是為了進一步建立、健全公司長效激勵機制,吸引和留住優秀人才,獎勵本公司的董事、高級管理人員、中層管理人員及核心骨幹成員的積極性,有效地將股東利益與本公司業務經營的負責人的利益結合起來,協助各訂約方共同關注本公司的長遠發展和前景。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.